article thumbnail

FTC and DOJ outline potential changes to agencies’ review of pharmaceutical mergers

JD Supra: Mergers

On June 1, 2023, the Federal Trade Commission (FTC) and the Antitrust Division of the US Department of Justice (DOJ) released a summary of a workshop jointly held by the agencies in June 2022 titled “Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers.”

article thumbnail

Healthcare & Life Sciences Private Equity Deal Tracker: Hamilton Lane Acquires Stake in Avista-Backed Cosette Pharmaceuticals

JD Supra: Mergers

Hamilton Lane has acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors, according to a news release. By: McGuireWoods LLP

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTC and DOJ Antitrust Memorialize Joint Workshop on the Future of Antitrust Enforcement in the Pharmaceutical Industry

JD Supra: Mergers

Department of Justice Antitrust Division, recently released a summary of the Agencies’ June 2022 joint workshop titled “The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers.” By: Mintz

article thumbnail

Chancery Determines Pharmaceutical Company Complied with Merger Agreement’s Requirement To Use Commercially Reasonable Efforts

JD Supra: Mergers

Cephalon, Inc., 2018-0075-SG (Del. 30, 2024) - Stockholder representatives of an acquired corporation brought claims alleging that defendants had failed to use contractually-required commercially reasonable efforts to commercialize an acquired drug asset for a particular use. By: Morris James LLP

article thumbnail

The European Commission report on competition enforcement in the pharmaceutical sector

JD Supra: Mergers

On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding market participants and consumers, particularly amid the challenges posed by the Covid-19 crisis.

article thumbnail

The FTC "Settles" For a Conduct Consent Decree to Resolve Its Challenge to the Amgen-Horizon Merger

JD Supra: Mergers

For years, the antitrust enforcement agencies have indicated their antipathy toward resolving competition issues in proposed mergers by entering into consent decrees that prohibit certain conduct, rather than stopping the merger entirely or fixing the competition issues through divestitures. By: Mintz - Antitrust Viewpoints

Mergers 175
article thumbnail

Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.

Global Newswire by Notified: M&A

Nika Pharmaceuticals, Inc. OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.